Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity-Reference-Cited by-全球学者库

Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity

Published:2023-04 Issue: Volume:133 Page:106405
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Zhao Zean,Luo Jian,Liao Hui,Zheng Fengxin,Chen Xinhua,Luo Jiajun,Chen Yongjun,Zhao Kunlu,Zhang Shuqin,Tian Jinhong,Wu Ting,Li Yongmei,Li Lu,Yang Yang,Lin Cuiting,Zhang Qun,Tian Yuanxin,Pang Jianxin

Funder

Sun Yat-sen University

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference66 articles.

1. Hyperuricemia and gout; the role of diet;Alvarez-Lario;Nutr. Hosp.,2014

2. Decreased extra-renal urate excretion is a common cause of hyperuricemia;Ichida;Nat. Commun.,2012

3. Recent advances on uric acid transporters;Xu;Oncotarget,2017

4. Renal transport of uric acid: evolving concepts and uncertainties;Bobulescu;Adv. Chronic Kidney Dis.,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023);Bioorganic Chemistry;2024-02

2. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25

3. Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation;Journal of Natural Products;2023-08-25